{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T16:44:42Z","timestamp":1794242682334,"version":"4.9.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,6,18]],"date-time":"2022-06-18T00:00:00Z","timestamp":1655510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,18]],"date-time":"2022-06-18T00:00:00Z","timestamp":1655510400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"University of Bern"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Gynecol Obstet"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>The intention of this systematic review was to analyze the literature on breast cancer (BC) and the use of the levonorgestrel-releasing intrauterine system (LNG-IUS).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The literature was searched in Medline, Embase, Cochrane Library, CINAHL, Web of Science and ClinicalTrials.com and included search terms related to breast cancer and LNG-IUS. After elimination of duplicates, 326 studies could be identified and were assessed according to inclusion and exclusion criteria. In the end, 10 studies met the defined criteria and were included in the systematic review.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>6 out of the 10 selected studies were cohort studies, three were case\u2013control studies and one a systematic review\/meta-analysis. 6 found a positive association between BC and the use of LNG-IUS. One study only found an increased risk for invasive BC in the subgroup of women aged 40\u201345\u00a0years. In contrast, three studies showed no indication of a higher BC risk.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The results imply an increased BC risk in LNG-IUS users, especially in postmenopausal women and with longer duration of use. Positive effects of the LNG-IUS such as reduced risks for other hormonal cancers have been observed, were, however, not focus of this systematic review. The heterogeneity of the analyzed studies and vast number of confounding factors call for further investigations in this issue. Patients should be advised according to their individual risk profile and hormone-free alternatives may be considered for women with a history of BC.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00404-022-06640-y","type":"journal-article","created":{"date-parts":[[2022,6,18]],"date-time":"2022-06-18T04:02:26Z","timestamp":1655524946000},"page":"1747-1761","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Influence of the levonorgestrel-releasing intrauterine system on the risk of breast cancer: a systematic review"],"prefix":"10.1007","volume":"307","author":[{"given":"Aline","family":"Z\u00fcrcher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Knabben","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidrun","family":"Janka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5591-1552","authenticated-orcid":false,"given":"Petra","family":"Stute","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,18]]},"reference":[{"issue":"3","key":"6640_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"HFJ Sung","year":"2021","unstructured":"Sung HFJ, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F (2021) Global cancer statistics 2020: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):209\u2013249. https:\/\/doi.org\/10.3322\/caac.21660","journal-title":"CA Cancer J Clin"},{"issue":"10286","key":"6640_CR2","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1016\/S0140-6736(20)32381-3","volume":"397","author":"S Loibl","year":"2021","unstructured":"Loibl S, Poortmans P, Morrow M, Denkert C, Curigliano G (2021) Breast cancer. Lancet 397(10286):1750\u20131769. https:\/\/doi.org\/10.1016\/S0140-6736(20)32381-3","journal-title":"Lancet"},{"issue":"4","key":"6640_CR3","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1001\/jama.2020.9482","volume":"324","author":"RT Chlebowski","year":"2020","unstructured":"Chlebowski RT, Anderson GL, Aragaki AK et al (2020) Association of menopausal hormone therapy with breast cancer incidence and mortality during long-term follow-up of the women\u2019s health initiative randomized clinical trials. JAMA 324(4):369\u2013380. https:\/\/doi.org\/10.1001\/jama.2020.9482","journal-title":"JAMA"},{"issue":"10\u201311","key":"6640_CR4","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/s0039-128x(00)00122-7","volume":"65","author":"MC Pike","year":"2000","unstructured":"Pike MC, Ross RK (2000) Progestins and menopause: epidemiological studies of risks of endometrial and breast cancer. Steroids 65(10\u201311):659\u2013664. https:\/\/doi.org\/10.1016\/s0039-128x(00)00122-7","journal-title":"Steroids"},{"key":"6640_CR5","doi-asserted-by":"publisher","first-page":"430","DOI":"10.2165\/00002018-199615060-00006","volume":"15","author":"F Sturridge","year":"1996","unstructured":"Sturridge F (1996) A risk-benefit assessment of the levonorgestrel-releasing intrauterine system. Drug Saf 15:430\u2013444. https:\/\/doi.org\/10.2165\/00002018-199615060-00006","journal-title":"Drug Saf"},{"key":"6640_CR6","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1991.tb37898.x","author":"T Luukkainen","year":"1990","unstructured":"Luukkainen T (1990) Levonorgestrel releasing intrauterine device. Ann Med. https:\/\/doi.org\/10.1111\/j.1749-6632.1991.tb37898.x","journal-title":"Ann Med"},{"issue":"8","key":"6640_CR7","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1111\/aogs.13817","volume":"99","author":"L Conz","year":"2020","unstructured":"Conz L, Mota BS, Bahamondes L et al (2020) Levonorgestrel-releasing intrauterine system and breast cancer risk: a systematic review and meta-analysis. Acta Obstet Gynecol Scand 99(8):970\u2013982. https:\/\/doi.org\/10.1111\/aogs.13817","journal-title":"Acta Obstet Gynecol Scand"},{"issue":"1","key":"6640_CR8","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1007\/s10549-017-4491-2","volume":"167","author":"N Siegelmann-Danieli","year":"2018","unstructured":"Siegelmann-Danieli N, Katzir I, Landes JV et al (2018) Does levonorgestrel-releasing intrauterine system increase breast cancer risk in peri-menopausal women? An HMO perspective. Breast Cancer Res Treat 167(1):257\u2013262. https:\/\/doi.org\/10.1007\/s10549-017-4491-2","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"6640_CR9","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.ygyno.2018.02.006","volume":"149","author":"M Jareid","year":"2018","unstructured":"Jareid M, Thalabard JC, Aarflot M, Bovelstad HM, Lund E, Braaten T (2018) Levonorgestrel-releasing intrauterine system use is associated with a decreased risk of ovarian and endometrial cancer, without increased risk of breast cancer. Results from the Nowac study. Gynecol Oncol 149(1):127\u2013132. https:\/\/doi.org\/10.1016\/j.ygyno.2018.02.006","journal-title":"Gynecol Oncol"},{"issue":"23","key":"6640_CR10","doi-asserted-by":"publisher","first-page":"2228","DOI":"10.1056\/NEJMoa1700732","volume":"377","author":"LS Morch","year":"2017","unstructured":"Morch LS, Skovlund CW, Hannaford PC, Iversen L, Fielding S, Lidegaard O (2017) Contemporary hormonal contraception and the risk of breast cancer. N Engl J Med 377(23):2228\u20132239. https:\/\/doi.org\/10.1056\/NEJMoa1700732","journal-title":"N Engl J Med"},{"issue":"2","key":"6640_CR11","doi-asserted-by":"publisher","first-page":"188","DOI":"10.3109\/0284186X.2015.1062538","volume":"55","author":"T Soini","year":"2016","unstructured":"Soini T, Hurskainen R, Grenman S et al (2016) Levonorgestrel-releasing intrauterine system and the risk of breast cancer: a nationwide cohort study. Acta Oncol 55(2):188\u2013192. https:\/\/doi.org\/10.3109\/0284186X.2015.1062538","journal-title":"Acta Oncol"},{"key":"6640_CR12","doi-asserted-by":"publisher","DOI":"10.1007\/s10552-015-0702-5","author":"S Heikkinen","year":"2015","unstructured":"Heikkinen S, Koskenvuo M, Malila N, Sarkeala T, Pukkala E, Pitkaniemi J (2015) Use of exogenous hormones and the risk of breast cancer: results from self-reported survey data with validity assessment. Cancer Causes Control. https:\/\/doi.org\/10.1007\/s10552-015-0702-5","journal-title":"Cancer Causes Control"},{"issue":"2 Pt 1","key":"6640_CR13","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1097\/AOG.0000000000000356","volume":"124","author":"T Soini","year":"2014","unstructured":"Soini T, Hurskainen R, Grenman S, Maenpaa J, Paavonen J, Pukkala E (2014) Cancer risk in women using the levonorgestrel-releasing intrauterine system in Finland. Obstet Gynecol 124(2 Pt 1):292\u2013299. https:\/\/doi.org\/10.1097\/AOG.0000000000000356","journal-title":"Obstet Gynecol"},{"issue":"3","key":"6640_CR14","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.contraception.2010.11.009","volume":"83","author":"J Dinger","year":"2011","unstructured":"Dinger J, Bardenheuer K, Minh TD (2011) Levonorgestrel-releasing and copper intrauterine devices and the risk of breast cancer. Contraception 83(3):211\u2013217. https:\/\/doi.org\/10.1016\/j.contraception.2010.11.009","journal-title":"Contraception"},{"issue":"2","key":"6640_CR15","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/ijc.24738","volume":"126","author":"HK Lyytinen","year":"2010","unstructured":"Lyytinen HK, Dyba T, Ylikorkala O, Pukkala EI (2010) A case-control study on hormone therapy as a risk factor for breast cancer in Finland: intrauterine system carries a risk as well. Int J Cancer 126(2):483\u2013489. https:\/\/doi.org\/10.1002\/ijc.24738","journal-title":"Int J Cancer"},{"issue":"4","key":"6640_CR16","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1097\/01.AOG.0000178754.88912.b9","volume":"106","author":"T Backman","year":"2005","unstructured":"Backman T, Rauramo I, Jaakkola K et al (2005) Use of the levonorgestrel-releasing intrauterine system and breast cancer. Obstet Gynecol 106(4):813\u2013817. https:\/\/doi.org\/10.1097\/01.AOG.0000178754.88912.b9","journal-title":"Obstet Gynecol"},{"key":"6640_CR17","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1016\/S0140-6736(97)08233-0","volume":"350","author":"Cancer CGoHFiB","year":"1997","unstructured":"Cancer CGoHFiB (1997) Breast cancer and hormone replacement therapy: collaborative reanalyses of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 350:1047\u20131059","journal-title":"Lancet"},{"issue":"9382","key":"6640_CR18","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/s0140-6736(03)14065-2","volume":"362","author":"V Beral","year":"2003","unstructured":"Beral V (2003) Breast cancer and hormone-replacement therapy in the million women study. Lancet 362(9382):419\u2013427. https:\/\/doi.org\/10.1016\/s0140-6736(03)14065-2","journal-title":"Lancet"},{"issue":"4","key":"6640_CR19","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.bpobgyn.2014.10.010","volume":"29","author":"MW Seif","year":"2015","unstructured":"Seif MW, Diamond K, Nickkho-Amiry M (2015) Obesity and menstrual disorders. Best Pract Res Clin Obstet Gynaecol 29(4):516\u2013527. https:\/\/doi.org\/10.1016\/j.bpobgyn.2014.10.010","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"key":"6640_CR20","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/S0140-6736(08)60269-X","volume":"371","author":"ATM Renehan","year":"2008","unstructured":"Renehan ATM, Egger M et al (2008) Body mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 371:569\u2013578. https:\/\/doi.org\/10.1016\/S0140-6736(08)60269-X","journal-title":"Lancet"},{"issue":"4","key":"6640_CR21","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1055\/s-2001-18644","volume":"19","author":"PTJ Pakarinen","year":"2001","unstructured":"Pakarinen PTJ, Luukkainen T (2001) Therapeutic use of the LNG IUS, and counseling. Semin Reprod Med 19(4):365\u2013372. https:\/\/doi.org\/10.1055\/s-2001-18644","journal-title":"Semin Reprod Med"},{"key":"6640_CR22","doi-asserted-by":"publisher","DOI":"10.1002\/ijgo.13737","author":"GFM D'Alessandro","year":"2021","unstructured":"D\u2019Alessandro GFM, Barra F, Costantini S, Gustavino C, Ferrero S (2021) Systematic review and meta-analysis on the impact of the levonorgestrel-releasing intrauterine system in reducing risk of ovarian cancer. Int J Gynaecol Obstet. https:\/\/doi.org\/10.1002\/ijgo.13737","journal-title":"Int J Gynaecol Obstet"},{"issue":"9017","key":"6640_CR23","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1016\/s0140-6736(96)90806-5","volume":"347","author":"Cancer CGoHFiB","year":"1996","unstructured":"Cancer CGoHFiB (1996) Breast cancer and hormonal contraceptives: Collaborative reanalysis of individual data on 53,297 women with breast cancer and 100,239 women without breast cancer from 54 epidemiological studies. Lancet 347(9017):1713\u20131727. https:\/\/doi.org\/10.1016\/s0140-6736(96)90806-5","journal-title":"Lancet"}],"container-title":["Archives of Gynecology and Obstetrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00404-022-06640-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00404-022-06640-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00404-022-06640-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,28]],"date-time":"2023-04-28T09:10:45Z","timestamp":1682673045000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00404-022-06640-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,18]]},"references-count":23,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,6]]}},"alternative-id":["6640"],"URL":"https:\/\/doi.org\/10.1007\/s00404-022-06640-y","relation":{},"ISSN":["1432-0711"],"issn-type":[{"value":"1432-0711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,18]]},"assertion":[{"value":"10 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}